Clinical trials: Sorafenib
Hepatocellular Carcinoma
Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment
Researchers already did trials that showed Sorafenib and Regorafenib worked for patients with hepatocellular carcinoma (most common liver tumor type).
- Trial name
- SORAGO-HCC (NCT03644511)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Sorafenib (Nexavar, BAY43-9006)
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Bayer
Kidney Cancer
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900536
- Testing
- mutation analysis, polymorphism analysis, protein expression analysis
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Hepato Cellular Carcinoma (HCC)
First Line Hepato Cellular Carcinoma (HCC)
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
- Trial name
- BRISK FL (NCT00858871)
- Testing
- Brivanib, Sorafenib
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,714 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well sorafenib works in treating patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00238212
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT05121571
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Glioblastoma, Gliosarcoma
Sorafenib in Newly Diagnosed High Grade Glioma
This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination with Temodar and radiation therapy in patients with newly diagnosed high grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
- Trial name
- NCT00884416
- Testing
- Sorafenib dose escalation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Geneva
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).
- Trial name
- NCT02627963
- Testing
- Tivozanib hydrochloride, Sorafenib
- Where
- 191 sites in United States, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Lung Cancer
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Open label study of sorafenib
- Trial name
- NCT00456716
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Swedish Medical Center
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
The purpose of this study is to assess the safety and determine MTD (maximal tolerated doses) and recommended doses of neoadjuvant sorafenib (BAY 43-9006) and concurrent sorafenib, cisplatin and radiation in the locally advanced…
- Trial name
- NCT00627835
- Testing
- sorafenib, sorafenib and cisplatin
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Cancer
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients
- Trial name
- NCT00562913
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Bayer
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm
- Trial name
- NCT01445080
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Where
- 25 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
- Trial name
- NCT02240433
- Testing
- LY2157299, Sorafenib
- Where
- 3 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Renal Cell
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have been administered with Nexavar for unresectable or advanced renal cell carcinoma (RCC).
- Trial name
- NCT01411423
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 3,305 people
- Sponsor
- Bayer
Thyroid Cancer
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
The purpose of this study is to find out what effects, good and/or bad, the combination of sorafenib and temsirolimus will have on thyroid cancer.
- Trial name
- NCT01025453
- Testing
- Temsirolimus and Sorafenib
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00722072
- Testing
- fulvestrant, sorafenib tosylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Carcinoma, Hepatocellular
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
This study investigates the safety and efficacy of the combination therapy with BAY86-9766 and sorafenib in patients with liver cancer. Safety will be determined by laboratory and other evaluations.
- Trial name
- BASIL (NCT01204177)
- Testing
- BAY86-9766 MEK Inhibitor + Sorafenib
- Where
- 15 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 70 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
The purpose of the study is to observe the effect of sorafenib combined with aspirin in preventing the recurrence in high-risk patients with hepatocellular carcinoma.
- Trial name
- NCT02748304
- Testing
- control, sorafenib, aspirin
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Programmed Cell Death 1
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously…
- Conditions
- Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy
- Trial name
- NCT05420922
- Testing
- Lenvatinib Oral Product, PD-1 inhibitor, Local treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital